Seres Therapeutics Inc. (NASDAQ:MCRB)’s share price traded down 5.8% during trading on Friday . The company traded as low as $11.05 and last traded at $11.13, with a volume of 659,216 shares trading hands. The stock had previously closed at $11.82.

A number of equities analysts have recently commented on the stock. Canaccord Genuity restated a “buy” rating on shares of Seres Therapeutics in a research report on Sunday, May 29th. Cowen and Company reiterated a “buy” rating on shares of Seres Therapeutics in a research report on Tuesday, July 19th. FBR & Co reiterated a “buy” rating on shares of Seres Therapeutics in a research report on Monday, May 2nd. HC Wainwright began coverage on shares of Seres Therapeutics in a research report on Friday, July 29th. They set a “buy” rating and a $50.00 target price for the company. Finally, Leerink Swann reiterated a “buy” rating and set a $12.00 target price on shares of Seres Therapeutics in a research report on Thursday, August 11th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. Seres Therapeutics has an average rating of “Buy” and an average target price of $31.57.

The company has a 50-day moving average of $22.28 and a 200-day moving average of $26.31. The firm’s market cap is $444.62 million.

Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Thursday, August 11th. The company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by $0.24. During the same quarter last year, the firm posted ($1.45) EPS. The business earned $3 million during the quarter, compared to analyst estimates of $4.20 million. The firm’s revenue for the quarter was up NaN% on a year-over-year basis. On average, analysts predict that Seres Therapeutics Inc. will post ($2.32) EPS for the current fiscal year.

In other Seres Therapeutics news, insider Michele Trucksis sold 4,156 shares of the stock in a transaction on Thursday, July 28th. The stock was sold at an average price of $35.18, for a total value of $146,208.08. Following the sale, the insider now owns 4,156 shares in the company, valued at $146,208.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Ventures Fund 2007 L. Flagship sold 1,000,000 shares of the firm’s stock in a transaction on Wednesday, May 25th. The shares were sold at an average price of $27.60, for a total value of $27,600,000.00. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Seres Therapeutics stock. Jennison Associates LLC boosted its stake in shares of Seres Therapeutics Inc. (NASDAQ:MCRB) by 1.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 398,959 shares of the company’s stock after buying an additional 7,259 shares during the period. Jennison Associates LLC owned 1.02% of Seres Therapeutics worth $13,999,000 as of its most recent SEC filing.

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.